NEW YORK, July 22, 2026, 04:21 (EDT)
- Shares finished Tuesday at $8.10, a rise of 790.11%, after reaching a high of $19.19.
- The company stated there was no significant corporate development behind the unusual activity.
- Shares granted for two patents account for 61.7% of the most recently disclosed total.
China Pharma Holdings, Inc. NYSEAMERICAN:CPHI stated there was no significant development to account for Tuesday’s 790% jump. The sharp move also shifted the value of two February patent deals.
China Pharma granted 25 million shares in exchange for the two patents. Priced at $8.10 per share, the total notional value for this block amounted to $202.5 million.
The deals closed at $14.994 million. Based on Tuesday’s closing price, the stake is valued at 13.5 times that amount.
The shares accounted for 61.7% of the most recently reported total. Based on an initial estimate, the reported shares have a total value of approximately $328.2 million.
This implied valuation amounts to 83.4 times first-quarter sales on an annualised basis. The figure is intended for illustration only and does not represent company guidance.
NYSE American ended its session at 04:21 EDT. The pre-opening session begins at 06:30, with regular trading opening at 09:30.
In the last seven days, the stock climbed from $0.61 to $8.10, marking a gain of 1,228%.
The company issued its second statement in six days without a catalyst. A July 15 announcement referred to unusual trading activity on three previous occasions.
The company stated it had “not aware of any material corporate developments.” It advised investors to “exercise care” and depend on official disclosures. PR Newswire
Volume figures for Tuesday varied between data vendors. MarketWatch reported 93.61 million shares traded, while StockAnalysis listed 83.48 million. Each total was more than double the most recently reported share count.
The February deals highlight the extent of the repricing:
| Patent transfer | Shares issued | Issue price | Recorded value | Notional value at $8.10 |
|---|---|---|---|---|
| Topiroxostat patent | 12.4 million | $0.63 | $7.812 million | $100.44 million |
| Prinsepia patent | 12.6 million | $0.57 | $7.182 million | $102.06 million |
| Total | 25.0 million | — | $14.994 million | $202.50 million |
Initial notional figures are calculated by multiplying the number of issued shares with Tuesday’s closing value. These figures do not represent a revaluation of the patents for accounting treatment.
Revenue for the first quarter declined 13.4% to $983,536, while net loss increased 45.5% to $1.14 million.
As of March 31, cash totaled $168,474. Current liabilities were $5.26 million greater than current assets. Intangible assets made up 85.7% of total assets.
Management determined that there was significant uncertainty regarding the company’s capacity to remain a going concern. The firm noted that it might need to secure additional debt or equity financing.
There will be five standard sessions until July 28. Investors will assess if trading volume stays high following two statements that offered no new developments.
Risks: High price volatility, requirements for additional funding, and a potential equity offering increase risk of loss. China’s centralized procurement has further lowered certain product sales.
Tuesday’s closing level stayed roughly 58% under the intraday high. Price discovery continues to be unstable.
Related articles: Pharmaceuticals
